Jazz Pharmaceuticals plc (JAZZ) stock
Close on Nov 11, 2026Market cap $16.11BP/E 80.9Yield –
Jazz Pharmaceuticals plc grew revenue 13.5% to $4.72B over the twelve months to Sep 30, 2026. Free cash flow was $1.62B, up 21.3% from a year earlier. At the latest close the market valued the company at $16.11B, 80.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $16.11B
- P/E ratio
- 80.9
- Price to sales
- 3.42
- Price to book
- 3.84
- Dividend yield
- –
- Free cash flow yield
- 10.06%
Fundamentals
- Revenue
- $4.72B
- Net income
- $205.95M
- EPS, diluted
- $3.07
- Free cash flow
- $1.62B
- Book value per share
- $64.79
- Diluted shares
- 65M
Trading
- Next earnings
- Feb 23, 2027 (estimated, after the close)
- Previous close
- $245.43
- Open
- $244.24
- Day's range
- $243.76 – $248.97
- Volume
- 592,854
- Average volume (20 days)
- 828,102
- Index membership
- Russell 1000 (since Sep 2022)
- Beta (5 years)
- 0.54
- 52-week range
- $132.10 – $266.38
- RSI (14 days)
- 68.0
- Volatility (1 year)
- 38.7%
- Relative volume
- 0.69×
- WACC
- 7.0%
Index membership is inferred from the holdings of funds that track each index (IWB), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | JAZZ | S&P 500 | Difference | JAZZ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +13.7% | -2.4% | +16.1 pts | ||
| 3 months | +0.1% | -1.2% | +1.3 pts | ||
| Year to date | +46.0% | +12.3% | +33.7 pts | ||
| 1 year | +81.1% | +12.4% | +68.6 pts | ||
| 3 years | +106.5% | +78.8% | +27.7 pts | +27.3% | +21.4% |
| 5 years | +83.2% | +75.2% | +8.1 pts | +12.9% | +11.9% |
| 10 years | +119.5% | +311.1% | −191.6 pts | +8.2% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Jazz Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- News
- News
- Update
About Jazz Pharmaceuticals
Pharmaceutical Preparations
Jazz Pharmaceuticals plc is a biopharmaceutical company that discovers, develops, and commercializes therapeutic medicines for patients facing rare diseases, particularly conditions with limited treatment options. The company focuses its portfolio across therapeutic areas addressing rare sleep disorders, rare epilepsies, and rare oncology. Key commercial products include Xywav and Xyrem for sleep disorders such as narcolepsy and idiopathic hypersomnia; Epidiolex for severe childhood-onset seizure syndromes including Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex; and oncology therapies such as Ziihera, Modeyso, Zepzelca, and Rylaze for diverse cancers. Its customers comprise adult and pediatric patients diagnosed with these targeted conditions.
Company profile, executives and historyJazz Pharmaceuticals stock: common questions
What is Jazz Pharmaceuticals's stock price?
JAZZ closed at $248.24 on Nov 11, 2026, up 1.14% on the day. Over the past 52 weeks it traded between $132.10 and $266.38.
What is Jazz Pharmaceuticals's market cap?
Jazz Pharmaceuticals was worth $16.11B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is JAZZ's P/E ratio?
JAZZ trades at 80.9 times earnings, based on diluted earnings per share of $3.07 over the twelve months to Sep 30, 2026.
How much revenue does Jazz Pharmaceuticals make?
Jazz Pharmaceuticals reported revenue of $4.72B for the twelve months to Sep 30, 2026, up 13.5% from a year earlier.
Does Jazz Pharmaceuticals pay a dividend?
No. Jazz Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Jazz Pharmaceuticals report earnings next?
Jazz Pharmaceuticals is expected to report Q4 FY2026 results on Feb 23, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has JAZZ stock performed over the past year?
Including dividends, JAZZ returned +81.1% over the past year, against +12.4% for the S&P 500.
How many JAZZ shares are sold short?
6M shares were sold short at the latest FINRA report, 9.25% of the float, or 7.7 days of average trading volume.
Who are Jazz Pharmaceuticals's competitors?
Companies most similar to Jazz Pharmaceuticals by business, industry and size include ALNY, PTCT, BMRN, INSM, SRPT.
See a number that looks wrong?